Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

This study is testing a combination of two drugs — nimotuzumab (a targeted antibody) and TGP (a plant-based chemotherapy drug) — as a first-line treatment for patients with nasopharyngeal carcinoma (cancer at the back of the nose and throat) that has come back or spread to other parts of the body. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with recurrent or metastatic nasopharyngeal carcinoma confirmed by biopsy - This is your first treatment for recurrent or metastatic disease (you have not yet received systemic therapy for the spread) - Your tumor tests positive for a protein called EGFR - You have at least one measurable tumor lesion - You are in reasonably good health (ECOG 0 or 2) and expected to survive at least 3 months **You may NOT be eligible if...** - You have already received systemic treatment for your recurrent or metastatic disease - Your tumor is EGFR-negative - You have serious heart, liver, kidney, or blood problems Talk to your doctor to see if this trial is right for you.